A Short Eulogy For The Rebate Rule
Executive Summary
The rebate rule is dead, but we should pay tribute to the failed endeavor.
You may also be interested in...
Pharma's Big Defeat: US Rebate Proposal Hits The End Of The Road
White House will not move forward with a rebate proposal the drug industry supported as a way to lower patient drug spending.
A Complete Retreat: “Protected Classes” Stay Protected In US Medicare
CMS has abandoned its plan to give private plans more leverage in the “protected” drug classes in Part D. It will probably be a long time before anyone tries to change the protected classes again.
Senate Commerce Leaders Want An FTC Study Into PBM Business Practices – And More
Committee Chair Maria Cantwell (D-Wash.) solicits advice from witnesses for additional authorities to conduct oversight of PBMs and pushes for a GAO study.